| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Ayrton Capital LLC | 9.9% | $967,625 | 774,100 | Ayrton Capital LLC | 31 Dec 2024 | |||
| INTRACOASTAL CAPITAL, LLC | 5% | $484,351 | 532,254 | Mitchell P. Kopin | 31 Dec 2025 |
As of 31 Dec 2025, 26 institutional investors reported holding 983,849 shares of PharmaCyte Biotech, Inc. - Common Stock, $0.0001 par value per share (PMCB). This represents 9.2% of the company’s total 10,666,413 outstanding shares.
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q4 | 983,849 | $711,966 | +$398,436 | $0.72 | 26 |
| 2025 Q3 | 433,038 | $419,849 | -$145,856 | $0.97 | 20 |
| 2025 Q2 | 576,518 | $632,075 | +$9,323 | $1.09 | 20 |
| 2025 Q1 | 567,925 | $709,896 | -$40,591 | $1.25 | 21 |
| 2024 Q4 | 600,392 | $934,269 | -$425,788 | $1.57 | 18 |
| 2024 Q3 | 825,885 | $1,577,022 | -$369,360 | $1.91 | 23 |
| 2024 Q2 | 1,031,877 | $2,021,917 | +$102,393 | $1.96 | 25 |
| 2024 Q1 | 977,850 | $2,316,963 | -$237,143 | $2.37 | 27 |
| 2023 Q4 | 1,088,077 | $2,346,525 | +$81,427 | $2.16 | 30 |
| 2023 Q3 | 1,142,621 | $2,398,471 | -$193,590 | $2.10 | 27 |
| 2023 Q2 | 1,212,969 | $3,468,135 | -$6,628,385 | $2.86 | 27 |
| 2023 Q1 | 3,527,753 | $10,222,132 | +$391,731 | $2.91 | 27 |
| 2022 Q4 | 3,391,314 | $9,931,381 | -$3,961,059 | $2.93 | 26 |
| 2022 Q3 | 4,983,776 | $11,962,579 | +$2,478,753 | $2.40 | 22 |
| 2022 Q2 | 3,920,480 | $8,791,603 | +$254,010 | $2.25 | 24 |
| 2022 Q1 | 3,839,722 | $8,829,619 | +$802,780 | $2.30 | 19 |
| 2021 Q4 | 3,469,931 | $8,676,673 | +$4,798,113 | $2.50 | 19 |
| 2021 Q3 | 1,394,523 | $4,420,853 | +$4,420,853 | $3.17 | 14 |